Compare TSBK & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | SLN |
|---|---|---|
| Founded | 1915 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.7M | 300.9M |
| IPO Year | 1997 | N/A |
| Metric | TSBK | SLN |
|---|---|---|
| Price | $42.18 | $6.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 17.9K | ★ 226.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 21.93 | N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.96 | $4.19 |
| 52 Week High | $43.58 | $8.40 |
| Indicator | TSBK | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 52.51 |
| Support Level | $37.50 | $5.77 |
| Resistance Level | $41.87 | $7.05 |
| Average True Range (ATR) | 1.09 | 0.54 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 51.73 | 68.46 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.